The first was lapatinib, an oral reversible TKI against EGFR and HER2, that, in a phase II trial, did not report responses in HER2 MUT NSCLC [71], so its investigation was withdrawn for lung cancer due to the lack of efficacy (NCT00073008). This evidence concerns the gene ERBB2 and lung carcinoma.